277 related articles for article (PubMed ID: 24373078)
1. Management of HCV transplant patients with triple therapy.
Coilly A; Roche B; Duclos-Vallée JC; Samuel D
Liver Int; 2014 Feb; 34 Suppl 1():46-52. PubMed ID: 24373078
[TBL] [Abstract][Full Text] [Related]
2. Current management and perspectives for HCV recurrence after liver transplantation.
Coilly A; Roche B; Samuel D
Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
[TBL] [Abstract][Full Text] [Related]
4. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.
Coilly A; Roche B; Duclos-Vallée JC; Samuel D
Liver Int; 2015 Jan; 35 Suppl 1():44-50. PubMed ID: 25377540
[TBL] [Abstract][Full Text] [Related]
5. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
[TBL] [Abstract][Full Text] [Related]
6. Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.
Roche B; Coilly A; Roque-Afonso AM; Samuel D
Viruses; 2015 Sep; 7(9):5155-68. PubMed ID: 26404355
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
Coilly A; Dumortier J; Botta-Fridlund D; Latournerie M; Leroy V; Pageaux GP; Agostini H; Giostra E; Moreno C; Roche B; Antonini TM; Guillaud O; Lebray P; Radenne S; Saouli AC; Calmus Y; Alric L; Debette-Gratien M; De Ledinghen V; Durand F; Duvoux C; Samuel D; Duclos-Vallée JC
PLoS One; 2015; 10(9):e0138091. PubMed ID: 26394142
[TBL] [Abstract][Full Text] [Related]
8. How to optimize current therapy of HCV genotype 1 infection with boceprevir.
Bourlière M; Adhoute X; Wendt A; Ansaldi C; Oules V; Castellani P
Liver Int; 2014 Feb; 34 Suppl 1():4-10. PubMed ID: 24373071
[TBL] [Abstract][Full Text] [Related]
9. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis C virus infection after liver transplantation.
Agarwal K; Barnabas A
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S349-54. PubMed ID: 24091115
[TBL] [Abstract][Full Text] [Related]
11. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
13. Management of HCV patients with cirrhosis with direct acting antivirals.
Boccaccio V; Bruno S
Liver Int; 2014 Feb; 34 Suppl 1():38-45. PubMed ID: 24373077
[TBL] [Abstract][Full Text] [Related]
14. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
[TBL] [Abstract][Full Text] [Related]
15. News and challenges in the treatment of hepatitis C in liver transplantation.
Coilly A; Roche B; Duclos-Vallée JC; Samuel D
Liver Int; 2016 Jan; 36 Suppl 1():34-42. PubMed ID: 26725895
[TBL] [Abstract][Full Text] [Related]
16. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
17. Management of recurrent hepatitis C virus after liver transplantation.
Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
[TBL] [Abstract][Full Text] [Related]
18. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
20. Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
